Augmented renal clearance (ARC) and Meropenem concentration

Evaluation of prevalence of Augmented renal clearance (ARC) and serum concentration of Meropenem with two different dosing regimens in critically ill patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120703010178N19

Enrollment

Registered

2020-02-07

Start date

2019-06-22

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Augmented renal clearance (ARC).

Interventions

Intervention group: Patients with creatinine clearance of more than or equal to 130 ml/min, based on 12-hr urine collection, who receive meropenem (Ronakpharm, Iran) will be recruited in the study. St

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: serum creatinin 0.7mg/dl and lower Sequential Organ Failure Assessment (SOFA) score 4 and lower Augmented renal clearance (ARC ) scoring 7 and higher Augmented renal clearance in trauma intensive Care (ARCTIC) scoring 7 and higher 12 hour - Clearance creatinin 130 ml/min and higher

Exclusion criteria

Exclusion criteria: Pregnancy and Lactation Age lower than 18 yr

Design outcomes

Primary

Measure	Time frame
Serum concentration of Meropenem. Timepoint: 1 hour after end of infusion, 30 minute before next dose. Method of measurement: HPLC.;Serum creatinin. Timepoint: Daily from the beginning of the study to the 14th day of the study. Method of measurement: Laboratory apparatus, Calorimetric method.;Urine volume. Timepoint: 0,3,7,10,14 day of enter to study. Method of measurement: Urine bag.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Sistanizad

Shahid Beheshti University of Medical Sciences

sistanizadm@sbmu.ac.ir+98 21 8820 0118

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026